CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. High threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increased Drug Development Activities
3.4.1.2. Patient Compliance offered by pharmaceutical suspensions
3.4.1.3. Availability of generic pharmaceutical suspensions
3.4.2. Restraints
3.4.2.1. Limited drug compatibility
3.4.3. Opportunities
3.4.3.1. Growing initiatives for market expansion
CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Oral
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Parenteral
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Infectious Diseases
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Gastrointestinal
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Neurological
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Home Care Settings
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Drug Store and Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Providers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Type
8.2.3. Market size and forecast, by Indication
8.2.4. Market size and forecast, by End User
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Type
8.2.6.1.2. Market size and forecast, by Indication
8.2.6.1.3. Market size and forecast, by End User
8.2.6.1.4. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Type
8.2.6.2.2. Market size and forecast, by Indication
8.2.6.2.3. Market size and forecast, by End User
8.2.6.2.4. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Type
8.2.6.3.2. Market size and forecast, by Indication
8.2.6.3.3. Market size and forecast, by End User
8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Type
8.3.3. Market size and forecast, by Indication
8.3.4. Market size and forecast, by End User
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Type
8.3.6.1.2. Market size and forecast, by Indication
8.3.6.1.3. Market size and forecast, by End User
8.3.6.1.4. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Type
8.3.6.2.2. Market size and forecast, by Indication
8.3.6.2.3. Market size and forecast, by End User
8.3.6.2.4. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Type
8.3.6.3.2. Market size and forecast, by Indication
8.3.6.3.3. Market size and forecast, by End User
8.3.6.3.4. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Type
8.3.6.4.2. Market size and forecast, by Indication
8.3.6.4.3. Market size and forecast, by End User
8.3.6.4.4. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Type
8.3.6.5.2. Market size and forecast, by Indication
8.3.6.5.3. Market size and forecast, by End User
8.3.6.5.4. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Type
8.3.6.6.2. Market size and forecast, by Indication
8.3.6.6.3. Market size and forecast, by End User
8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Type
8.4.3. Market size and forecast, by Indication
8.4.4. Market size and forecast, by End User
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Type
8.4.6.1.2. Market size and forecast, by Indication
8.4.6.1.3. Market size and forecast, by End User
8.4.6.1.4. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Type
8.4.6.2.2. Market size and forecast, by Indication
8.4.6.2.3. Market size and forecast, by End User
8.4.6.2.4. Market size and forecast, by Distribution Channel
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Type
8.4.6.3.2. Market size and forecast, by Indication
8.4.6.3.3. Market size and forecast, by End User
8.4.6.3.4. Market size and forecast, by Distribution Channel
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Type
8.4.6.4.2. Market size and forecast, by Indication
8.4.6.4.3. Market size and forecast, by End User
8.4.6.4.4. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Type
8.4.6.5.2. Market size and forecast, by Indication
8.4.6.5.3. Market size and forecast, by End User
8.4.6.5.4. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Type
8.4.6.6.2. Market size and forecast, by Indication
8.4.6.6.3. Market size and forecast, by End User
8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Type
8.5.3. Market size and forecast, by Indication
8.5.4. Market size and forecast, by End User
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Type
8.5.6.1.2. Market size and forecast, by Indication
8.5.6.1.3. Market size and forecast, by End User
8.5.6.1.4. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Type
8.5.6.2.2. Market size and forecast, by Indication
8.5.6.2.3. Market size and forecast, by End User
8.5.6.2.4. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Type
8.5.6.3.2. Market size and forecast, by Indication
8.5.6.3.3. Market size and forecast, by End User
8.5.6.3.4. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Type
8.5.6.4.2. Market size and forecast, by Indication
8.5.6.4.3. Market size and forecast, by End User
8.5.6.4.4. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Pfizer Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Merck & Co., Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. AstraZeneca plc
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Eli Lilly and Company.
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Bayer AG
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Sanofi
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Lupin
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Glenmark Pharmaceuticals Limited
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Novartis AG
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Teva Pharmaceutical Industries Limited
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
| ※参考情報 薬物懸濁液（Pharmaceutical Suspension）は、薬物を液体中に均一に分散させた製剤の一種です。この製剤は、固体の薬物成分が液体媒体の中で浮遊している状態を指します。懸濁液は、特に水に溶解しにくい薬物の投与を可能にするために開発されており、その安定性や効果的な薬物放出を実現します。 薬物懸濁液の種類はさまざまで、主に以下のように分類されます。第一に、経口用懸濁液です。これは、主に内服用として使用され、液体状の投与がしやすい特徴があります。例えば、子供や高齢者など、嚥下困難な患者に対して有効です。第二に、注射用懸濁液があります。これは、静脈内または筋肉内に注射するための製剤であり、高濃度での薬効を持つ薬物が使用されることが一般的です。第三に、外用懸濁液も存在します。これは皮膚や粘膜に直接適用するために使用され、炎症や感染症の治療に役立ちます。 用途に関しては、薬物懸濁液はさまざまな場面で使用されています。特に、抗生物質や抗炎症薬、抗ウイルス薬など、さまざまな低水溶性薬物の投与に利用されます。薬物の効果を最大限に引き出すために、懸濁液は固体成分が均一に分散されるように調整されており、患者の容体や治療目的に応じた製剤になります。また、急速に効果を発現させるために、懸濁液の粒子が特定のサイズに調整されることもあります。 薬物懸濁液の製造には、いくつかの関連技術が利用されています。まず、粉砕技術があります。これは固体薬物を微細化するプロセスであり、より均一な懸濁液を得るために必要です。次に、乳化技術も重要です。懸濁液の安定性を確保するために、適切な乳化剤や安定化剤が用いられます。これにより、懸濁状態が長時間維持されることが可能になります。 さらに、薬物の放出速度や生物学的利用能を調整するための技術も存在します。例えば、制御放出技術により、薬物の放出速度を調整することで、持続的な治療効果を実現します。また、ナノテクノロジーを利用した懸濁液も開発されており、より効果的な薬物治療を目指すための研究が進められています。 製剤の品質管理も重要な側面です。懸濁液は、物理的性質や化学的安定性を維持するために厳格な基準が設けられています。製品の一貫した品質を確保するために、粒子サイズ分布や濃度、pHなどが定期的にチェックされています。 薬物懸濁液は、その特性から、患者の服用のしやすさや治療効果の向上に寄与する重要な製剤です。特に、飲み込みにくい固形薬の代替として、また特定の治療条件下での迅速な薬効を発揮する手段としての位置づけが確立されています。これにより、さまざまな疾患治療において欠かせない役割を果たしています。今後も新しい技術の導入や改良により、薬物懸濁液の品質や効能を向上させることが期待されています。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
